著者

梶本 修身

出版者

大阪外国語大学

雑誌

大阪外国語大学論集 (ISSN:09166637)

巻号頁・発行日

vol.19, pp.143-150, 1998-09-30

---

A randomized, double-blind, cross-over trial was carried out in 20 out-patients with asthenopia to compare the efficiency of oral treatment with 62.25mg of Vaccinium myrtillus anthocyanoside or placebo daily in two divided for 8 weeks. 10 typical symptoms of asthenopia,for instant,eye strain, visual haziness, headache etc., were scored at 2 weeks intervals. Critical fusion frequency of flicker and visual analogue scale of general fatigue were also recorded before and after each treatment. During first 4 weeks, each symptom improved in both groups, but in the group treated with the Vaccinium myrtillus anthocyanoside to a faster and greater extent During the maintenance periods, a further significant improvement was recorded in the patients treated with the Vaccinium myrtillus anthocyanoside in 6 of 10 symptoms, whereas in those on placebo the symptoms didn't improved any more. Although there is no significant difference on the effects between the Vaccinium myrtillus anthocyanoside and placebo in the other 4 symptoms, the percentage of improvement in the group treated with Vaccinium myrtillus anthocyanoside, was higher than that with placebo. The Vaccinium myrtillus anthocyanoside also improved the critical fusion of flicker and visual analogue scale of general fatigue more significantly than did placebo. Clinical tolerance was excellent with all treatments, with no complaints being recorded. So it's suggested that oral treatment with the Vaccinium myrtillus anthocyanoside should be basic therapy for the management of asthenopia.